Logo image of MD.CA

MIDLAND EXPLORATION INC (MD.CA) Stock Fundamental Analysis

TSX-V:MD - TSX Venture Exchange - CA59751U1003 - Common Stock - Currency: CAD

0.325  0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MD. MD was compared to 805 industry peers in the Metals & Mining industry. The financial health of MD is average, but there are quite some concerns on its profitability. MD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year MD has reported negative net income.
MD had a negative operating cash flow in the past year.
In the past 5 years MD always reported negative net income.
In the past 5 years MD always reported negative operating cash flow.
MD.CA Yearly Net Income VS EBIT VS OCF VS FCFMD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

With a decent Return On Assets value of -5.62%, MD is doing good in the industry, outperforming 69.32% of the companies in the same industry.
MD has a better Return On Equity (-5.87%) than 71.93% of its industry peers.
Industry RankSector Rank
ROA -5.62%
ROE -5.87%
ROIC N/A
ROA(3y)-4.08%
ROA(5y)-3.65%
ROE(3y)-4.23%
ROE(5y)-3.79%
ROIC(3y)N/A
ROIC(5y)N/A
MD.CA Yearly ROA, ROE, ROICMD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3 -4

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD.CA Yearly Profit, Operating, Gross MarginsMD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

5

2. Health

2.1 Basic Checks

MD does not have a ROIC to compare to the WACC, probably because it is not profitable.
MD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MD has more shares outstanding
The debt/assets ratio for MD has been reduced compared to a year ago.
MD.CA Yearly Shares OutstandingMD.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MD.CA Yearly Total Debt VS Total AssetsMD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 9.36 indicates that MD is not in any danger for bankruptcy at the moment.
The Altman-Z score of MD (9.36) is better than 72.17% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that MD is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, MD perfoms like the industry average, outperforming 50.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 9.36
ROIC/WACCN/A
WACC8.71%
MD.CA Yearly LT Debt VS Equity VS FCFMD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 4.08 indicates that MD has no problem at all paying its short term obligations.
The Current ratio of MD (4.08) is better than 70.56% of its industry peers.
A Quick Ratio of 4.08 indicates that MD has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.08, MD is doing good in the industry, outperforming 70.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
MD.CA Yearly Current Assets VS Current LiabilitesMD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2

3. Growth

3.1 Past

The earnings per share for MD have decreased strongly by -41.05% in the last year.
MD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -58.69%.
The Revenue has been growing by 42.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-41.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.68%
Revenue 1Y (TTM)-58.69%
Revenue growth 3Y-1.2%
Revenue growth 5Y42.06%
Sales Q2Q%-69.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MD.CA Yearly Revenue VS EstimatesMD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MD.CA Price Earnings VS Forward Price EarningsMD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MD.CA Per share dataMD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

MD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

MIDLAND EXPLORATION INC

TSX-V:MD (7/17/2025, 7:00:00 PM)

0.325

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)05-09 2025-05-09
Earnings (Next)08-13 2025-08-13
Inst Owners24.14%
Inst Owner ChangeN/A
Ins Owners4.89%
Ins Owner ChangeN/A
Market Cap30.43M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 208.69
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.43
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.62%
ROE -5.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.08%
ROA(5y)-3.65%
ROE(3y)-4.23%
ROE(5y)-3.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10317%
Cap/Sales 1960.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z 9.36
F-Score2
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)12561.2%
Cap/Depr(5y)13783.8%
Cap/Sales(3y)1602.19%
Cap/Sales(5y)4631.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.68%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-58.69%
Revenue growth 3Y-1.2%
Revenue growth 5Y42.06%
Sales Q2Q%-69.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.5%
OCF growth 3YN/A
OCF growth 5YN/A